Tides Express | Ribo Life Science (6938.HK) Successfully Listed on the Main Board of HKEX

Jan 19, 2026 09:30 CST Updated 09:30

Ribo Life Science

Small Nucleic Acid Drug Developer

｜Edited by the Content Team of Zhong肽 Biochemical

2026YearJanuary9Day,Suzhou Ribo Life Science Co., Ltd., a leading small nucleic acid drug company("Ribo Life Science" or "the Company," stock code: 06938.HK) officially listed on the Main Board of the Hong Kong Stock Exchange, marking a capitalization breakthrough for Chinese pharmaceutical companies in the siRNA innovative drug sector, injecting new momentum into industry development.

This global offering,Ribo Life ScienceA total of 31,610,400 shares were issued at a price of HKD 57.97 per share, raising over HKD 1.8 billion in total.The public offering portion of this IPO was oversubscribed by more than 100 times, while the international offering portion was subscribed 16.7 times, reflecting global investors' high recognition of the value of the small nucleic acid sector and the company's strength.The proceeds from this IPO will provide solid financial support for the advancement of the company's core business. Meanwhile, the issuance has attracted 12 heavyweight cornerstone investors, including China Asset Management, Dacheng International and Dacheng Fund, and Taikang Life Insurance, demonstrating the firm confidence of top-tier institutions in the company’s long-term prospects.

The funds raised will focus on four major directions: advancing global multicenter clinical research for core products; supporting preclinical and clinical stage development of the R&D pipeline; iteratively upgrading small nucleic acid delivery technologies and other platforms; and supplementing working capital and general corporate purposes.

As a pioneer in the industry, Ribo Life Science has built a full-technology-chain R&D platform with independent intellectual property rights, featuring its innovative liver-targeting RiboGalSTAR.^TMDelivery technology has successfully advanced multiple products into Phase II clinical trials. The company has established research and development centers in Kunshan, Beijing, and Gothenburg, Sweden, forming an international R&D system with comprehensive capabilities spanning from early-stage research to global clinical development.

AboutRibo Life Science

Suzhou Ribo Life Science Co., Ltd. (6938.HK) is a global biopharmaceutical company dedicated to the development and commercialization of small interfering RNA (siRNA) drugs. Powered by its self-innovated small nucleic acid technology platform, the company has established a rich and differentiated product pipeline focused on major disease areas such as cardiometabolic disorders, liver, and kidney diseases. Ribo Life Science is committed to providing revolutionary treatment solutions for patients worldwide through continuous innovation.

Source:

1Ribo Life Science